Between its $12 billion deal to acquire CareFusion in 2014 and a $24 billion deal to buy C.R. Bard, Becton Dickinson made some key offloads and is investing $100 million in its Nebraska plant to boost its insulin syringe manufacturing.
A couple years ago, C.R. Bard CEO Timothy Ring revealed a strategic investment plan to drive the company toward growth. Under Ring’s stewardship, the company delivered on that plan in 2015 with a 3% increase in revenue.